<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01119066</url>
  </required_header>
  <id_info>
    <org_study_id>10-050</org_study_id>
    <nct_id>NCT01119066</nct_id>
  </id_info>
  <brief_title>HLA-Compatible Related or Unrelated Donors With CD34+ Enriched, T-cell Depleted Peripheral Blood Stem Cells Isolated by the CliniMACS System in the Treatment of Patients With Hematologic Malignancies</brief_title>
  <official_title>A Phase II Trial of Transplants From HLA-Compatible Related or Unrelated Donors With CD34+ Enriched, T-cell Depleted Peripheral Blood Stem Cells Isolated by the CliniMACS System in the Treatment of Patients With Hematologic Malignancies and Other Lethal Hematologic Disorders</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Memorial Sloan Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Memorial Sloan Kettering Cancer Center</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to find out the effects of using a system called CliniMACS to&#xD;
      remove Tcells from blood stem cells. Removing T-cells may help stop a side effect called&#xD;
      Graft-Versus-Host Disease (GVHD). Some studies have been done with CliniMACS, but the Food&#xD;
      and Drug Administration (FDA) has not yet approved it.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 3, 2010</start_date>
  <completion_date type="Actual">March 30, 2021</completion_date>
  <primary_completion_date type="Actual">March 30, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To assess the incidence of durable hematopoietic engraftment for T-cell depleted transplants fractionated by the CliniMACS system administered after each of the four disease targeted cytoreduction regimens.</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>To assess the incidence and severity of acute and chronic GVHD following T-cell depleted, CD34+ progenitor cell enriched transplants fractionated by the CliniMACS system.</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>To assess the incidence of non-relapse mortality (transplant-related mortality) following each cytoreduction regimen and a transplant fractionated by the CliniMACS system.</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>To estimate the probability of survival and disease-free survival (DFS)</measure>
    <time_frame>at 6 months post transplant</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>To estimate the probability of survival and disease-free survival (DFS)</measure>
    <time_frame>1 year post transplant</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>To estimate the probability of survival and disease-free survival (DFS)</measure>
    <time_frame>2 years post transplant</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To determine the proportion of patients receiving optimal CD34+ (&gt; 5x106/kg) and CD3+ (&lt;1x105/kg) cell doses the proportion recurring suboptimal doses (&lt; 2x106/kg) CD34+ cells; and the proportion of patients receiving CD3+ T-cell doses &gt; 1x105/kg.</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To correlate doses of CD34+ progenitors and CD3+ T cells with engraftment, graft vs. host disease and non-relapse mortality.</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">422</enrollment>
  <condition>Acute Lymphoblastic Leukemia</condition>
  <condition>Acute Myelogenous Leukemia</condition>
  <condition>Myelodysplastic Syndrome</condition>
  <condition>Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>Total Body Irradiation, Thiotepa and Cyclophosphamide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Hyperfractionated total body irradiation to a dose of 1375-1500 cGy (depending on age, stage of disease and requirement of general anesthesia) with lung shielding) Thiotepa (5 mg/kg/day x 2 or 10 mg/kg/day x 1) Cyclophosphamide (60 mg/kg/day x 2) (or fludarabine 25mg/m2 x 5 if cyclophosphamide is contraindicated)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Busulfan, Melphalan and Fludarabine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Busulfan (0.8 mg/kg every 6 hours x 10 or 12 doses), (depending on disease) with dose modified according to pharmacokinetics Melphalan (70mg/m2/day x 2 ) Fludarabine (25mg/m2/ day x 5)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Clofarabine, Melphalan and Thiotepa</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Clofarabine (20mg/m2/ day x 5) (or, for children &lt;18 years of age, 30mg/m2/day x 5 if deemed suitable and with PI approval), Melphalan (70 mg/m2/day x 2) Thiotepa (5 mg/kg/day x 2 or 10mg/kg/day x1)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Melphalan, Fludarabine and Thiotepa</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Melphalan (70 mg/m2/day x 2) Fludarabine (25mg/m2/ day x 5 ) Thiotepa (5 mg/kg/day x 2 or 10mg/kg/day x1)</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>total body irradiation</intervention_name>
    <description>dose of 1375-1500 cGy</description>
    <arm_group_label>Total Body Irradiation, Thiotepa and Cyclophosphamide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Thiotepa</intervention_name>
    <description>5 mg/kg/day x 2 or 10 mg/kg/day x 1</description>
    <arm_group_label>Clofarabine, Melphalan and Thiotepa</arm_group_label>
    <arm_group_label>Melphalan, Fludarabine and Thiotepa</arm_group_label>
    <arm_group_label>Total Body Irradiation, Thiotepa and Cyclophosphamide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>60 mg/ kg/day x 2 (or fludarabine 25mg/m2 x 5 if cyclophosphamide is contraindicated).</description>
    <arm_group_label>Total Body Irradiation, Thiotepa and Cyclophosphamide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Busulfan</intervention_name>
    <description>0.8 mg/kg every 6 hours x 10 or 12 doses (depending on disease) with dose modified according to pharmacokinetics</description>
    <arm_group_label>Busulfan, Melphalan and Fludarabine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Melphalan</intervention_name>
    <description>70mg/m2/day x 2</description>
    <arm_group_label>Busulfan, Melphalan and Fludarabine</arm_group_label>
    <arm_group_label>Clofarabine, Melphalan and Thiotepa</arm_group_label>
    <arm_group_label>Melphalan, Fludarabine and Thiotepa</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine</intervention_name>
    <description>25mg/m2/ day x 5</description>
    <arm_group_label>Busulfan, Melphalan and Fludarabine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clofarabine</intervention_name>
    <description>20mg/m2/ day x 5 (or, for children &lt;18 years of age, 30mg/m2/day x 5 if deemed suitable and with PI approval)</description>
    <arm_group_label>Clofarabine, Melphalan and Thiotepa</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>(CliniMACS) T-cell depleted PBSC Transplant</intervention_name>
    <arm_group_label>Busulfan, Melphalan and Fludarabine</arm_group_label>
    <arm_group_label>Clofarabine, Melphalan and Thiotepa</arm_group_label>
    <arm_group_label>Melphalan, Fludarabine and Thiotepa</arm_group_label>
    <arm_group_label>Total Body Irradiation, Thiotepa and Cyclophosphamide</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Malignant conditions or other life threatening disorders correctable by transplant for&#xD;
             which CD34+ selected, T-cell depleted allogeneic hematopoietic stem cell&#xD;
             transplantation is indicated such as:&#xD;
&#xD;
          -  AML in 1st remission - for patients whose AML does not have 'good risk' cytogenetic&#xD;
             features (i.e. t 8;21, t15;17, inv 16).&#xD;
&#xD;
          -  Secondary AML in 1st remission&#xD;
&#xD;
          -  AML in 1st relapse or &gt; than or = to 2nd remission&#xD;
&#xD;
          -  ALL/CLL in 1st remission clinical or molecular features indicating a high risk for&#xD;
             relapse; or ALL/CLL &gt; than or = to 2nd remission&#xD;
&#xD;
          -  CML failing to respond to or not tolerating Imatinib or dasatinib in first chronic&#xD;
             phase of disease; CML in accelerated phase second chronic phase or in CR after&#xD;
             accelerated phase or blast crisis.&#xD;
&#xD;
          -  Non-Hodgkins lymphoma with chemoresponsive disease in any of the following categories:&#xD;
&#xD;
               1. intermediate or high grade lymphomas who have failed to achieve a first CR or&#xD;
                  have relapsed following a 1st remission who are not candidates for autologous&#xD;
                  transplants.&#xD;
&#xD;
               2. any NHL in remission which is considered not curable with chemotherapy alone and&#xD;
                  not eligible/appropriate for autologous transplant.&#xD;
&#xD;
          -  Myelodysplastic syndrome (MDS): RA//RARS/RCMD with high risk cytogenetic features or&#xD;
             transfusion dependence as well as RAEB-1 and RAEB-2 and Acute myelogenous leukemia&#xD;
             (AML) evolved from MDS, who are not eligible for transplantation and/or unable to&#xD;
             enroll onto protocol IRB 08-008.&#xD;
&#xD;
          -  Chronic myelomonocytic leukemia: CMML-1 and CMML-2.&#xD;
&#xD;
          -  Multiple Myeloma with disease in the following categories:&#xD;
&#xD;
               1. Patients with relapsed multiple myeloma following autologous stem cell&#xD;
                  transplantation who have achieved at least partial response following additional&#xD;
                  chemotherapy.&#xD;
&#xD;
               2. Patients with high risk cytogenetics at diagnosis must have achieved a partial&#xD;
                  response following autologous stem cell transplantation. Patients must have&#xD;
                  complex karyotype, del17p, t4;14 and/or t14;16 by FISH and/or del13 by&#xD;
                  karyotyping.&#xD;
&#xD;
          -  Other rare lethal disorders of Hematopoiesis and Lymphopoiesis for which a T-cell&#xD;
             depleted transplant is indicated (e.g. hemophagocytic lymphohistiocytosis; refractory&#xD;
             aplastic anemia or congenital cytopenias; non-SCID lethal genetic immunodeficiencies&#xD;
             such as Wiskott Aldrich Syndrome, CD40 ligand deficiency, or ALPS, as well as&#xD;
             refractory autoimmune cytopenias, PNH, metabolic storage diseases or heavily&#xD;
             transfused congenital hemoglobinopathies).&#xD;
&#xD;
          -  Accrual to each treatment arm will include up to 30 standard risk and 30 poor risk&#xD;
             patients (60 patients/treatment arm) except for Regimen D, which will include 30&#xD;
             patients/treatment arm, all of which will be poor risk by virtue of risks of relapse&#xD;
             and/or transplant related mortality.&#xD;
&#xD;
          -  Standard risk patients will include eligible patients, as defined above, who are&#xD;
             receiving transplants as treatment for MDS in RA//RARS/RCMD, AML in 1st or 2nd&#xD;
             remission, ALL in 1st CR, NHL in 1st remission, MM in 1st remission, Very Good Partial&#xD;
             Response, or 1st Partial Response or CML in the first chronic phase or 1st remission.&#xD;
&#xD;
          -  All other patients, including those with treatment related malignancies and/or those&#xD;
             who have AML derived from MDS, will have received extensive prior chemo/radiotherapy&#xD;
             and, therefore, will be considered to be at poor risk of conditioning and transplant&#xD;
             related morbidities, and potentially transplant related mortality. Patients with life&#xD;
             threatening non-malignant genetic and acquired disorders will also, by virtue of their&#xD;
             history of, optional transfusions and/or infection be considered poor risk. Stopping&#xD;
             rules for non-relapse related mortality in these heavily treated patients are,&#xD;
             therefore, slightly less stringent than patients in the poor risk transplant groups.&#xD;
             Stopping rules for the principal endpoints of graft failure and GvHD are the same for&#xD;
             all groups.&#xD;
&#xD;
        The following inclusion criteria are also required:&#xD;
&#xD;
          -  Patient's age includes from birth on to &lt; 70 years old.&#xD;
&#xD;
          -  Patients may be of either gender or any ethnic background.&#xD;
&#xD;
          -  Patients must have a Karnofsky (adult) or Lansky (pediatric) Performance Status &gt; or =&#xD;
             to 70%&#xD;
&#xD;
          -  Patients must have adequate organ function measured by:&#xD;
&#xD;
        Cardiac: asymptomatic or if symptomatic then LVEF at rest must be &gt; or = to 50% and must&#xD;
        improve with exercise.&#xD;
&#xD;
        Hepatic: &lt; 3x ULN AST and â‰¤ to 1.5 total serum bilirubin, unless there is congenital benign&#xD;
        hyperbilirubinemia or if the hyperbilirubinemia is directly caused by the disease in which&#xD;
        the patient is receiving a transplant (e.g. AML Chloroma obstructing the biliary tree).&#xD;
        Patients with higher bilirubin levels due to causes other than active liver disease are&#xD;
        also eligible with PI approval e.g. patients with PNH, Gilbert's disease or other hemolytic&#xD;
        disorders.&#xD;
&#xD;
        Renal: serum creatinine &lt; than or = to 1.2 mg/dl or if serum creatinine is outside the&#xD;
        normal range, then CrCl &gt; 40 ml/min (measured or calculated/estimated) Pulmonary:&#xD;
        asymptomatic or if symptomatic, DLCO &gt; or = to 50% of predicted (corrected for hemoglobin)&#xD;
&#xD;
          -  Each patient must be willing to participate as a research subject and must sign an&#xD;
             informed consent form.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Female patients who are pregnant or breast-feeding&#xD;
&#xD;
          -  Active viral, bacterial or fungal infection&#xD;
&#xD;
          -  Patient seropositive for HIV-I/II; HTLV -I/II&#xD;
&#xD;
          -  Presence of leukemia in the CNS.&#xD;
&#xD;
        Donor Inclusion Criteria:&#xD;
&#xD;
          -  Each donor must meet criteria outlined by institutional guidelines&#xD;
&#xD;
          -  Donor should agree to undergo general anesthesia and bone marrow harvest collection if&#xD;
             PBSC yield is inadequate or otherwise not transplantable for whatever reason.&#xD;
&#xD;
        Donor Exclusion Criteria&#xD;
&#xD;
          -  If donors do not meet institutional guidelines, exclusion will be considered.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>69 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Richard O'Reilly, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mskcc.org</url>
    <description>Memorial Sloan Kettering Cancer Center</description>
  </link>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>May 4, 2010</study_first_submitted>
  <study_first_submitted_qc>May 5, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 7, 2010</study_first_posted>
  <last_update_submitted>May 17, 2021</last_update_submitted>
  <last_update_submitted_qc>May 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Leukemia</keyword>
  <keyword>Multiple Myeloma</keyword>
  <keyword>radiation</keyword>
  <keyword>Thiotepa</keyword>
  <keyword>cyclophosphamide</keyword>
  <keyword>fludarabine</keyword>
  <keyword>Clofarabine</keyword>
  <keyword>CliniMACS device</keyword>
  <keyword>GCSF</keyword>
  <keyword>10-050</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Hematologic Neoplasms</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Melphalan</mesh_term>
    <mesh_term>Busulfan</mesh_term>
    <mesh_term>Thiotepa</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Clofarabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

